Automated Insulin Delivery in Real Life (AID-IRL): Real-World User Perspectives on Commercial AID
- PMID: 32935554
- PMCID: PMC8861778
- DOI: 10.1177/1932296820957360
Automated Insulin Delivery in Real Life (AID-IRL): Real-World User Perspectives on Commercial AID
Abstract
Commercial automated insulin delivery (AID) systems are usually assessed based on clinical outcomes, ignoring uptake. A qualitative study evaluated user experiences when switching to currently available commercial AID. Interview feedback was coded on key themes including the adoption experience with regards to quality of life, clinical outcomes, and users' expectations. Most felt their learning curve was easy. Most saw reduced hypoglycemia and increased time in range, although there were outliers. Many mentioned post-meal hyperglycemia as an improvement area for commercial AID. Users with one particular continuous glucose monitor (CGM) type reported sleep disruption. Companies should consider real-world user feedback with regards to improving training materials for new users with less CGM experience and by improving target flexibility and postprandial algorithm performance, plus reducing manual interventions required by users.
Keywords: AID; APS; artificial pancreas; automated insulin delivery; closed loop; hybrid closed loop.
Conflict of interest statement
Figures
References
-
- Benhamou PY, Reznik Y. Closed-loop insulin delivery: understanding when and how it is effective. The Lancet Digital Health. 2020;2(2):e50-e51. - PubMed
-
- https://www.artificialpancreasbook.com/glossary. Acessed September 1, 2020.
-
- https://github.com/LoopKit/Loop. Acessed September 1, 2020.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous